Well, we have have half of BoM2 covered with Hepa, correct? Interestingly enough, while they have one hand on the IP with the debenture. Don't like the encumberment and risk with the IP, but Hepa has a lot of varied levels of interests with RVX, obviously. RVX should be able to come up with $6mm to unencumber the IP if push came to shove, even if it came directly out of the pockets of some of the principals, or at least kick the can down the road again while waiting for Covid results and a hopeful EUA application. All things and opportunities considered.

EUA following a good Covid trial is the key to such an important door, leading to actual revenues and real credibility and true excitement for other things coming potentially. Especially, if Canada, Brazil, and others placed some large orders. Fingers crossed tick tock